Pan-KRAS Inhibitor Programs
Oncology (unspecified cancers)
Pre-clinicalActive
Key Facts
Indication
Oncology (unspecified cancers)
Phase
Pre-clinical
Status
Active
Company
About BlossomHill Therapeutics
BlossomHill Therapeutics is a private, clinical-stage biotech company focused on developing intelligently designed small molecule drugs for oncology and autoimmune disorders. The company's pipeline is anchored by a first-in-class macrocyclic OMNI-EGFR inhibitor for NSCLC and new pan-KRAS inhibitor programs, indicating a focus on high-value, difficult-to-drug targets. With an $84 million financing round closed in late 2025, BlossomHill is well-capitalized to advance its clinical-stage assets, positioning it as an emerging player in the precision oncology and autoimmune therapy landscape.
View full company profileTherapeutic Areas
Other Oncology (unspecified cancers) Drugs
| Drug | Company | Phase |
|---|---|---|
| Microcystin-based ADC Payload | Simris Biologics | Pre-clinical |
| pHLA-targeting Biotherapeutics | BioCopy | Discovery/Pre-clinical |
| In vivo CAR-T programs | Interius BioTherapeutics | Pre-clinical |